Sino Biopharmaceutical Limited (OTCMKTS: SBMFF) is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China’s domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.
The company’s product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics. Its infusion solutions lineup includes glucose injections, sodium chloride injections, compound amino acid injections and heparin sodium injections. The small-molecule segment covers cardiovascular, analgesic, anti-infective and gastrointestinal therapies. In the biologics division, Sino Biopharmaceutical advances treatments in oncology, autoimmune disorders and metabolic diseases, leveraging both in-house R&D and collaborations with domestic and international research institutions.
Sino Biopharmaceutical serves primarily the mainland China market through an extensive network of sales subsidiaries, regional offices and distribution centers. The company operates multiple GMP-certified manufacturing facilities and continually invests in production capacity to meet rising domestic demand. While its core geographic exposure remains China, the firm is also exploring export opportunities in the Asia-Pacific region and other emerging markets.
Under the leadership of an experienced management team with deep expertise in drug development, regulatory affairs and commercial operations, Sino Biopharmaceutical continues to pursue strategic investments in technology platforms and pipeline assets. The company’s ongoing commitment to innovation and capacity expansion positions it to address evolving healthcare needs and support long-term growth in China’s pharmaceutical industry.
AI Generated. May Contain Errors.
